I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ASH 2023

-
Coming soon
10:00 PM
Duration 15mins Ballroom 20AB
Plasma Circulating Tumor DNA (ctDNA) as an Alternative to Tissue DNA for Genotyping of DLBCL: Results from the POLARIX Study
Jardin F, Raghavan V, Tracy S, Balasubramanian S, Sehn LH, Flowers CR, Morschhauser F, Herrera AF, Trněný M, Sharman JP, Salles G, Tilly H, Friedberg JW, Harris W, Hirata JH, Lee C, Jiang Y, Lenz G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 AM
Duration 2hrs San Diego, USA
The Cytogenetic and Molecular Testing Landscape in Patients with Newly Diagnosed Acute Myeloid Leukemia in Routine Clinical Practices in the United States
Bachiashvili K, Harada S, Ma E, Patel A, Wang R, Yellow-Duke A, Montez M, Chopra V, Bui CN, Vachhani P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
ASH 2023 Trials in progress: The randomized, double-blind, placebo-controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c trials – Crovalimab for vaso-occlusive episodes (VOEs) in sickle cell disease (SCD)
Araujo MA, Antmen B, Chite FA, Chonat S, de Franceschi L, Eleftheriou P, Inati A, Mahlangu J, Nur E, Payán Pernía S, Charania A, Gradinaru D, Hsia A, Luder Y, Perretti T, Sreckovic S, Bartolucci P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Co-expression of GPRC5D, FcRH5, and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma: Biomarker Results From the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
Dekhtiarenko I, Lelios I, Jacob W, Schneider M, Wiesser M, Carlo-Sella C, Manier S, Harrison SJ, Popat R, Hasselbalch Riley C, Bröske AME

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7
Kiialainen A, Pipe SW, Fijnvandraat K, Kenet G, Schmitt C, Buri M, Jimenez-Yuste V, Oldenburg J, Mancuso ME, Dhalluin C, Lehle M, Collins P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Experience with Emicizumab among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry
Poon MC, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Polito L, Moreno K, Santos M, Iserman E, Matino D, Iorio A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab
Harrup R, Kater AP, Eichhorst B, Owen C, Chyla B, Jin HY, Jiang Y, Chang YM, Millen R, Lefebure M, Thadani-Mulero M, Boyer M, Seymour JF

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium
Bottos A, Lutterbeck C, Bolen CR, Shin M, Bogard PE, Tabari E, Davies A, Knapp A, Nielsen T, Weigert O, Penuel E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
05:30 PM
Duration 15mins Grand Hall D
Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
Zelenetz A, Diefenbach C, Herbaux C, Tani M, Houot R, Bastos-Oreiro M, Tilly H, Gastinne T, Thieblemont C, Troy-Barnes E, Olivieri S, Kesavan M, Kanwar M, Barlera S, Hatzi K, Jiang Y, Boyer M, Morschhauser F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Seaport Ballroom ABCD
Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-cell Therapy and by Baseline Total Metabolic Tumor Volume
Hutchings M, Carlo-Stella C, Morschhauser F, Falchi L, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Baumlin P, Mulvihill E, Relf J, Chohan S, Kaufman D, Lundberg L, Dickinson M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:00 PM
Duration 15mins Room 29
Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe S, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Chang T, Lehle M, Niggli M, Fijnvandraat K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:30 AM
Duration 15mins Ballroom 20AB
Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients with Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw L-Y, Wu H, To I, Wei MC, Chavez JC

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 15mins Room 7
Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies
Röth A, Fu R, He G, Alzahrani H, Chou S, Hicheri Y, Kazmierczak M, Lacorte Recova V, Uchiyama M, Vladareanu A, Beveridge L, Buatois S, Buri M, Shi D, Balachandron N, Srekovic S, Scheinberg P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:45 AM
Duration 15mins Ballroom 20AB
Mosunetuzumab Monotherapy Demonstrates Activity and a Manageable Safety Profile in Patients with Relapsed or Refractory Richter’s Transformation
Cheah CY, Assouline S, Baker R, Bartlett NL, El-Sharkawi D, Giri P, Ku M, Schuster SJ, Matasar M, Radford J, Wei MC, Yin S, To I, Tracy S, Kwan A, Budde LE

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:00 AM
Duration 15mins Grand Hall C
Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-Up from a Pivotal Phase II Study
Schuster SJ, Sehn LH, Bartlett NL, Matasar M, Assouline S, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, To I, Tracy S, Kwan A, Penuel E, Budde LE

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:30 AM
Duration 15mins Grand Hall C
Preliminary findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide in Previously Untreated Follicular Lymphoma Requiring Therapy
Morschhauser F, Patel K, Cordoba R, Eyre TA, Bishton M, Houot R, Zhang H-L, Zou L, Osborne W, Galvez-Carvajal L, Thieblemont C, Yee DL, Knapp A, Purev E, Li H, Chen V, Banta KL, Sit J, Bachy E

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:00 AM
Duration 2hrs San Diego, USA
Dexamethasone is Associated With a Lower Incidence and Severity of Cytokine Release Syndrome Compared With Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Falchi L, Carlo-Stella C, Morschhauser F, Dickinson M, Bachy E, Cartron G, Khan C, Tani M, Martinez-Lopez J, Bartlett NL, Salar A, Brody J, Leppä S, Berthier A, Kallemeijn M, Relf J, Chohan S, Lundberg L, Hutchings M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
Phillips T, Matasar M, Eyre TA, Giné E, Filézac de L'Etang A, Byrne B, Lundberg L, Padovani A, Boetsch C, Bottos A, Qayum N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Cytokine Release Syndrome: The Patient, Carer, and Healthcare Professional Experience
Soong J, De Carlo G, Lasi-Tejani N, Sethi SK, Bolaños N, Elias M, Biru Y, Clavreul S, Chandler GS, Finzler K, Nouet Y, Del Santo A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study
Morschhauser F, Leung W, Raghavan V, Lenz G, Jardin F, Herrera AF, Sehn LH, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Tilly H, Herbaux C, Tracy S, Bolen CR, Harris W, Hirata JH, Lee C, Jiang Y, Batlevi CL, Salles G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL)
Hamidi H, Kimes P, Schroeder AV, Uzunovic J, Olszewski AJ, Sit J, Purev E, Yee D, McCord R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
New Tocilizumab (TCZ) Dosing Guidance for T-cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients With Relapsed/Refractory (R/R) B-cell non-Hodgkin Lymphoma (B-NHL): Insights From Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses
Jamois C, Turner DC, Gibiansky L, Li F, Frey N, Menuet J-F, Pereira LR, Lundberg L, Guerini E, Carlile D, Relf J, Wei MC, Kwan A, Grange S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Subcutaneous Mosunetuzumab is Active and has a Manageable Safety Profile in Patients With Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results From the Phase II MorningSun Study
Flinn IW, Budde LE, Tun AM, Burke JM, Anz B, Peles S, Sharman JP, Tumula PK, Biondo JML, Jani P, Wu M, Lin T, Parmar N, Mun Y, Yao N-S, Liu S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia
Ravelo A, Myers K, Ervin C, Brumble R, Bussberg C, Koffman B, Manzoor BS, Biondo JML, Mansfield C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Integrative Analysis of the Tumor Microenvironment to Model the Molecular Heterogeneity Correlating with Response to Cevostamab in Relapsed/Refractory Multiple Myeloma (RRMM)
Hamidi H, Nakamura R, Roy S, Rajasekaran K, Diaz G, Dos Santos C, Sumiyoshi T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Glofitamab Plus R-CHOP Induces High Response Rates With a Manageable Safety Profile in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study
Topp MS, Tani M, Dickinson M, Ghosh N, Santoro A, Pinto A, Bosch F, Fox CP, Lopez Guillermo A, Gastinne T, Viardot A, Townsend W, Qayum N, Barrett M, Kaufman D, Wu C, McCord R, Baumlin P, Kimes P, Morschhauser F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Unmet Medical Needs Amongst Older Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy: Experience from a Predominately United States Community Setting
Kadia T, Bataller A, Ma E, Patel A, Wang R, Yellow-Duke A, Montez M, Bui CN, Ravandi F

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
06:45 AM
Duration 15mins Grand Hall B
Fixed-Duration Mosun-Pola has Promising Efficacy and a Manageable Safety Profile in Patients with Prior-BTKi Treated Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study
Wang ML, Assouline S, Kamdar M, Ghosh N, Naik S, Nakhoda SK, Chavez J, Jia T, Pham S, Huw L-Y, Jing J, Ead W, To I, Batlevi CL, Wei MC, Budde LE

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:15 PM
Duration 15mins Seaport Ballroom ABCD
Mosunetuzumab and Polatuzumab Vedotin Demonstrate Preliminary Efficacy in Elderly Unfit and Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Olszewski AJ, Eradat H, Avigdor A, Horowitz NA, Babu S, Levi I, McKinney M, Lee ST, Burgues JMB, Rodriguez A, Bastos-Oreiro M, Ganzel C, Kim TM, Jeon Y-W, Taszner M, Narkhede M, Kim WS, Shin H-J, Lavie D, Woszczyk D, Dunshee D, Kapp AV, Zhou M, Batlevi CL, Ead W, Sellam G, Jurczak W

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Glofitamab Results in Cost Savings Versus Epcoritamab in Diffuse Large B-Cell Lymphoma (DLBCL): A Total Cost of Care Analysis
Mahmoudjafari Z, Di Maio D, Li J, Rosettie KL, Masaquel A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:00 AM
Duration 15mins Seaport Ballroom ABCD
Glofitamab Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated Large B-Cell Lymphoma Defined as High Risk by Circulating Tumor DNA: Preliminary Safety and Efficacy Results
Falchi L, Jardin F, Haioun C, Wrobel T, Joergensen J, Bastos-Oreiro M, Mou E, Martinez Lopez J, Budde LE, Bartlett NL, Zaucha JM, Garcia-Sancho AM, Shah R, Rees N, McCord R, Bazeos A, Tandon M, Doral M, Troy-Barnes E, Nijland M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:00 AM
Duration 2hrs San Diego, USA
Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced by Chimeric Antigen Receptor T-Cell Therapies Across Hematological Malignancies
Chaudhary N, Roy S, Lin C-F, Tandon M, Kwan A, Kuebler P, Shewade A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Panse J, Cermak J, Kyselova J, Gotoh A, Sahin F, Schrezenmeier H, Chang A, Gentile B, Uguen M, Han B

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Rculizumab: Results from the Phase III Randomized COMMODORE 2 Trial
Lundberg P, de la Iglesia S, Kelly R, Kulasekararaj A, Nishimura J, Risitano A, Röth A, Buatois S, Chebon S, Patel H, Kiialainen A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma Treated with Cevostamab in Phase I Study GO39775
Miglo J, Choeurng V, Nakamura R, Cooper J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study
Hutchings M, Avigdor A, Sureda A, Terol MJ, Bosch F, Corradini P, Stauffer Larsen T, Rueda Dominguez A, Skarbnik A, Jørgensen J, Lavie D, Gurion R, Zinzani PL, Pinto A, Cordoba R, Bottos A, Li D, Relf J, Filézac de L’Etang A, Sellam G, Gritti G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience
Jiménez-Yuste V, Lim E, Mistry K, Ventriglia G, Shapiro A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Quality of Life in Emicizumab-treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - An Assessment of Baseline PROMIS®-29 Scores
Buckner TW, Daoud N, Lee L, Lim E, Schwartz J, Raimundo K, Recht M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Early Intervention with Celmods, but Not Imids, Prevents Relapse to Forimtamig Driven By GPRC5D-Negative Myeloma Cells
Eckmann J, Lechner S, Bayer C, Hage C, Klein C, Umaña P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Early Prediction of Treatment Response by Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
Foerster AK

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 2hrs San Diego, USA
Identification of MYC-Driven High-Grade B-Cell Lymphoma Using Deep Learning-Based Whole-Slide Image Analysis
Yüce A, Doerig C, Gildenblat J, Abbasi-Sureshjani S, Mosinska A, Wright H, Leung W, Jiang Y, Kimes P, Laurent C, Korski K, Herrmann MD

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar